{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-016343","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2024-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.027312+00:00","generated_at":"2026-05-29T02:00:21.807273+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Corvus reports positive interim Phase 1 soquelitinib data in atopic dermatitis; $12.7M warrant exercise","bullets":["Soquelitinib 100mg BID: mean EASI reduction 55.9% at Day 28 vs 27% placebo; 69.1% at Day 58 vs 19.1% placebo.","At Day 58, 90% of soquelitinib patients achieved EASI-50, 40% EASI-75, 10% EASI-90 vs 25%, 0%, 0% for placebo.","No significant safety issues; only Grade 1 nausea (1 patient) and COVID-19 (1 patient) reported.","Samlyn Capital exercised all warrants for 3,633,978 shares, generating ~$12.7M cash proceeds.","Initial Cohort 2 data (200mg once daily) in 12 patients consistent with Cohort 1; no treatment-related AEs."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-016343","json":"https://secwatch.observer/filing/0001558370-24-016343.json","markdown":"https://secwatch.observer/filing/0001558370-24-016343.md","text":"https://secwatch.observer/filing/0001558370-24-016343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000155837024016343/0001558370-24-016343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000155837024016343/crvs-20241218x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:00:21.807273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}